Akihiko Yoshida

Summary

Affiliation: National Cancer Center
Country: Japan

Publications

  1. doi Anaplastic lymphoma kinase status in rhabdomyosarcomas
    Akihiko Yoshida
    Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan
    Mod Pathol 26:772-81. 2013
  2. doi ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases
    Akihiko Yoshida
    Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan
    Am J Surg Pathol 37:554-62. 2013
  3. doi NKX2.2 is a useful immunohistochemical marker for Ewing sarcoma
    Akihiko Yoshida
    Pathology and Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan
    Am J Surg Pathol 36:993-9. 2012
  4. doi MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype
    Akihiko Yoshida
    Departments of Pathology and Clinical Laboratories, National Cancer Center Research Institute, Tokyo, Japan
    Am J Surg Pathol 36:423-31. 2012
  5. doi c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas
    Koji Tsuta
    Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan
    J Thorac Oncol 7:331-9. 2012
  6. doi Comprehensive histologic analysis of ALK-rearranged lung carcinomas
    Akihiko Yoshida
    Pathology and Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan
    Am J Surg Pathol 35:1226-34. 2011
  7. doi The prognostic value of pfetin: a validation study in gastrointestinal stromal tumors using a commercially available antibody
    Daisuke Kubota
    Division of Pharmacoproteomics, National Cancer Center Research Institute, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Jpn J Clin Oncol 43:669-75. 2013
  8. doi Insulin-like growth factor-1 receptor protein expression and gene copy number alterations in non-small cell lung carcinomas
    Koji Tsuta
    Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo 104 0045, Japan
    Hum Pathol 44:975-82. 2013
  9. doi Clinicopathologic features and computed tomographic findings of 52 surgically resected adenosquamous carcinomas of the lung
    Yukio Watanabe
    Division of Pathology, National Cancer Center Hospital, Tokyo, Japan Department of Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan
    Ann Thorac Surg 97:245-51. 2014
  10. doi Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas
    Akihiko Yoshida
    Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Japan
    J Thorac Oncol 6:1677-86. 2011

Detail Information

Publications65

  1. doi Anaplastic lymphoma kinase status in rhabdomyosarcomas
    Akihiko Yoshida
    Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan
    Mod Pathol 26:772-81. 2013
    ....
  2. doi ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases
    Akihiko Yoshida
    Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan
    Am J Surg Pathol 37:554-62. 2013
    ..Fluorescence in situ hybridization signal patterns were unrelated to 5' fusion partner genes. All ROS1 fusion-positive tumors lacked alteration of EGFR, KRAS, HER2, ALK, and RET genes...
  3. doi NKX2.2 is a useful immunohistochemical marker for Ewing sarcoma
    Akihiko Yoshida
    Pathology and Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan
    Am J Surg Pathol 36:993-9. 2012
    ..All the other non-Ewing tumors tested were negative for this marker. NKX2.2 is a valuable marker for Ewing sarcoma, with a sensitivity of 93% and a specificity of 89%, and aids in the differential diagnosis of small round cell tumors...
  4. doi MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype
    Akihiko Yoshida
    Departments of Pathology and Clinical Laboratories, National Cancer Center Research Institute, Tokyo, Japan
    Am J Surg Pathol 36:423-31. 2012
    ....
  5. doi c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas
    Koji Tsuta
    Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan
    J Thorac Oncol 7:331-9. 2012
    ..The aim of this study was to examine the correlations between c-MET/phospho-MET expression as well as MET gene copy number alterations and overall survival (OS) in non-small cell lung carcinomas (NSCLCs)...
  6. doi Comprehensive histologic analysis of ALK-rearranged lung carcinomas
    Akihiko Yoshida
    Pathology and Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan
    Am J Surg Pathol 35:1226-34. 2011
    ..ALK-positive cancers commonly showed coexpression of thyroid transcription factor-1 and p63, and its significance is currently unclear...
  7. doi The prognostic value of pfetin: a validation study in gastrointestinal stromal tumors using a commercially available antibody
    Daisuke Kubota
    Division of Pharmacoproteomics, National Cancer Center Research Institute, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Jpn J Clin Oncol 43:669-75. 2013
    ..In the present study, we examine the usefulness of a commercially available polyclonal antibody against pfetin...
  8. doi Insulin-like growth factor-1 receptor protein expression and gene copy number alterations in non-small cell lung carcinomas
    Koji Tsuta
    Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo 104 0045, Japan
    Hum Pathol 44:975-82. 2013
    ..IGF-1R is highly expressed in SCC and mucinous ADC, although copy number alterations in the IGF-1R gene were rare. These findings may have important implications for future anti-IGF-1R therapeutic approaches...
  9. doi Clinicopathologic features and computed tomographic findings of 52 surgically resected adenosquamous carcinomas of the lung
    Yukio Watanabe
    Division of Pathology, National Cancer Center Hospital, Tokyo, Japan Department of Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan
    Ann Thorac Surg 97:245-51. 2014
    ..We studied the clinicopathologic features and computed tomographic (CT) findings of ASC and assessed the effect of tumor location and the extent of the AC component in ASC on the clinical and radiologic characteristics of ASC...
  10. doi Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas
    Akihiko Yoshida
    Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Japan
    J Thorac Oncol 6:1677-86. 2011
    ..In this study, we explored the potential of the ALK-break-apart chromogenic in situ hybridization (CISH) method to detect ALK-rearranged lung cancer...
  11. doi The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations
    Koji Tsuta
    Division of Pathology and Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan
    Lung Cancer 81:371-6. 2013
    ....
  12. doi Validation study on pfetin and ATP-dependent RNA helicase DDX39 as prognostic biomarkers in gastrointestinal stromal tumour
    Daisuke Kubota
    Division of Pharmacoproteomics, National Cancer Center Research Institute, Tokyo, Japan
    Jpn J Clin Oncol 42:730-41. 2012
    ..Prognostic biomarkers have long been required for the optimal use of kinase inhibitors in gastrointestinal stromal tumour...
  13. doi Clinicopathologic analysis of multiple (five or more) atypical adenomatous hyperplasias (AAHs) of the lung: evidence for the AAH-adenocarcinoma sequence
    Akiko Miyagi Maeshima
    Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan
    J Thorac Oncol 5:466-71. 2010
    ..Clarification of the clinicopathologic characteristics of patients with multiple atypical adenomatous hyperplasias (AAHs)...
  14. doi Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics
    Akihiko Yoshida
    Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan
    Mod Pathol 23:1279-88. 2010
    ..MDM2 and CDK4 immunostains therefore reliably distinguish low-grade osteosarcoma from benign histological mimics, and their combination may serve as a useful adjunct in this difficult differential diagnosis...
  15. doi Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung
    Koji Tsuta
    Division of Pathology and Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan
    J Thorac Oncol 6:1190-9. 2011
    ..Recent clinical trials revealed that accurate histologic typing of non-small cell lung cancer, especially squamous cell carcinoma (SCC), is essential...
  16. doi Well-differentiated liposarcoma with low-grade osteosarcomatous component: an underrecognized variant
    Akihiko Yoshida
    Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan
    Am J Surg Pathol 34:1361-6. 2010
    ....
  17. doi Biomarker expression and druggable gene alterations for development of an appropriate therapeutic protocol for pulmonary adenosquamous carcinoma
    Yukio Watanabe
    Division of Pathology, National Cancer Centre Hospital, Tokyo, Japan Department of Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan Division of Thoracic Surgery, National Cancer Centre Hospital, Tokyo, Japan
    Histopathology . 2014
    ..The genetic features and biomarkers of ASC are not well known. Here, we attempted to identify potential therapeutic markers for ASC...
  18. doi Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas
    Hideyuki Arita
    Department of Neurosurgery and Neuro Oncology, National Cancer Center Hospital, Tokyo, Japan
    Brain Tumor Pathol 32:22-30. 2015
    ..Our assay is particularly useful for the analysis of a large number of specimens as in a retrospective clinical study for example...
  19. doi Revisiting TP53 Mutations and Immunohistochemistry-A Comparative Study in 157 Diffuse Gliomas
    Hirokazu Takami
    Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan Department of Neurosurgery, University of Tokyo, Tokyo, Japan
    Brain Pathol 25:256-65. 2015
    ..Staining interpretation by an independent observer yielded comparable accuracy. We thus propose p53 immunohistochemistry as a moderately sensitive and highly specific marker to predict TP53 mutation. ..
  20. doi Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers
    Akihiko Yoshida
    Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan
    Mod Pathol 27:711-20. 2014
    ....
  21. doi Pulmonary neuroendocrine tumors with nuclear inclusion
    Saori Kobayashi
    Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan
    Pathol Res Pract 209:574-7. 2013
    ..The mechanisms of nuclear inclusion differed, with one due to herniation of the cytoplasm into the nucleus (pseudoinclusion) and the other due to accumulation of biotin resulting from a CTNNB1 gene mutation. ..
  22. doi Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma
    Harumi Nakamura
    Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan
    J Clin Pathol 66:705-7. 2013
    ..In the present report, we describe aberrant ALK expression in a small proportion of pulmonary neuroendocrine carcinomas (NECs) that do not have ALK gene alteration...
  23. doi Clinical proteomics identified ATP-dependent RNA helicase DDX39 as a novel biomarker to predict poor prognosis of patients with gastrointestinal stromal tumor
    Kazutaka Kikuta
    Division of Pharmacoproteomics, National Cancer Center Research Institute, Japan
    J Proteomics 75:1089-98. 2012
    ..ATP-dependent RNA helicase DDX39, a novel biomarker for GIST likely to be associated with metastatic disease, can identify patients likely to benefit from new therapeutic strategies such as tyrosine kinase inhibitors...
  24. doi Steroid receptor expression in thymomas and thymic carcinomas
    Takahiro Mimae
    Pathology and Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan
    Cancer 117:4396-405. 2011
    ....
  25. doi Expression of squamous cell carcinoma markers and adenocarcinoma markers in primary pulmonary neuroendocrine carcinomas
    Kyohei Masai
    Division of Pathology and Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan
    Appl Immunohistochem Mol Morphol 21:292-7. 2013
    ..In our study, CK5/6 and desmocollin 3 were highly specific markers for SQC, and napsin A was highly specific for ADC. These markers are recommended for diagnosis of poorly differentiated non-small cell lung cancer...
  26. doi Primary lung adenocarcinoma with morule-like components: a unique histologic hallmark of aggressive behavior and EGFR mutation
    Koji Tsuta
    Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan Electronic address
    Lung Cancer 85:12-8. 2014
    ..The aim of the study was to outline the clinicopathologic features of this variant...
  27. doi Multinodular and vacuolating neuronal tumor of the cerebrum
    Shintaro Fukushima
    Division of Brain Tumor Translational Research, National Cancer Center Research Institute, 5 1 1 Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    Brain Tumor Pathol 32:131-6. 2015
    ..MVNTs are distinctive tumors that should be differentiated from ganglion cell tumors, dysembryoplastic neuroepithelial tumors, and malformation of cortical development. ..
  28. doi Short communication: sclerosing meningioma in the deep sylvian fissure
    Shintaro Fukushima
    Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    Brain Tumor Pathol 31:289-92. 2014
    ..This case is the first report of a sclerosing meningioma arising in the deep sylvian fissure. We discuss the therapeutic dilemma of this case with respect to the current literature. ..
  29. doi Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component
    Akihiko Yoshida
    Clinical Laboratory Division, National Cancer Center Hospital, Japan
    Lung Cancer 72:309-15. 2011
    ..The characteristic histology, immunoprofile, frequent ALK translocation, and total lack of EGFR or KRAS mutations, may suggest that Ad-SRCC forms a histologically/molecularly coherent subgroup of adenocarcinoma...
  30. doi p40 is the best marker for diagnosing pulmonary squamous cell carcinoma: comparison with p63, cytokeratin 5/6, desmocollin-3, and sox2
    Takahiro Tatsumori
    Department of Pathology and Clinical Laboratories, National Cancer Center Hospital Division of General Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan
    Appl Immunohistochem Mol Morphol 22:377-82. 2014
    ..5%) of 68 small cell lung carcinomas, and 1 (2.4%) of 41 mesotheliomas. p40 staining yields high sensitivity as well as high specificity for distinguishing SQC from ADC, neuroendocrine carcinomas, and malignant mesothelioma. ..
  31. doi STAT6 immunohistochemistry is helpful in the diagnosis of solitary fibrous tumors
    Akihiko Yoshida
    Departments of Pathology and Clinical Laboratory Neurosurgery and Neuro Oncology Musculoskeletal Oncology Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan
    Am J Surg Pathol 38:552-9. 2014
    ..Therefore, nuclear STAT6 immunoreactivity is a highly sensitive and specific marker of SFTs and can be helpful when diagnosis is inconclusive by conventional methods. ..
  32. doi High-grade lung adenocarcinoma with fetal lung-like morphology: clinicopathologic, immunohistochemical, and molecular analyses of 17 cases
    Shigeki Morita
    Department of Pathology and Clinical Laboratories, Thoracic Surgery Division, National Cancer Center Hospital, Japan
    Am J Surg Pathol 37:924-32. 2013
    ....
  33. doi HER2 gene mutations in non-small cell lung carcinomas: concurrence with Her2 gene amplification and Her2 protein expression and phosphorylation
    Mikiko Suzuki
    Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan Division of General Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan
    Lung Cancer 87:14-22. 2015
    ..The aim of the current study is to identify clinicopathological characteristics of HER2-mutated non-small cell lung carcinomas (NSCLCs) in conjunction with HER2 protein expression, gene amplification, and phosphorylation...
  34. pmc Unique mutation portraits and frequent COL2A1 gene alteration in chondrosarcoma
    Yasushi Totoki
    Division of Cancer Genomics, National Cancer Center Research Institute, Chuo Ku, Tokyo, 104 0045, Japan
    Genome Res 24:1411-20. 2014
    ..With the characteristic accumulative process of somatic changes as a background, molecular defects in chondrogenesis and aberrant epigenetic control are primarily causative of both benign and malignant cartilaginous tumors. ..
  35. doi Secondary glioblastomas with IDH1/2 mutations have longer glioma history from preceding lower-grade gliomas
    Makoto Ohno
    Department of Neurosurgery and Neuro Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    Brain Tumor Pathol 30:224-32. 2013
    ..The aggressive progression to sGBM-Wt suggest the need for more intense treatment to the IDH1/2 wild-type tumors...
  36. pmc Gene expression network analysis of ETV1 reveals KCTD10 as a novel prognostic biomarker in gastrointestinal stromal tumor
    Daisuke Kubota
    Division of Pharmacoproteomics, National Cancer Centre Research Institute, Tokyo, Japan
    PLoS ONE 8:e73896. 2013
    ..We also examined the clinical utility and functions of its downstream gene, potassium channel tetramerization domain containing protein 10 (KCTD10)...
  37. pmc Mouse model for ROS1-rearranged lung cancer
    Yasuhito Arai
    Division of Cancer Genomics, National Cancer Center Research Institute, Chuo Ku, Tokyo, Japan
    PLoS ONE 8:e56010. 2013
    ..These data suggest that the EZR-ROS1 is a pivotal oncogene in human NSCLC, and that this animal model could be valuable for exploring therapeutic agents against ROS1-rearranged lung cancer...
  38. doi The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma
    Yoshiki Kozu
    Division of Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan
    Lung Cancer 73:45-50. 2011
    ..The ability to detecting such mutations using immunohistochemistry (IHC) would be advantageous...
  39. ncbi Extraskeletal myxoid chondrosarcoma: a review of 23 patients treated at a single referral center with long-term follow-up
    Koichi Ogura
    Division of Musculoskeletal Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Arch Orthop Trauma Surg 132:1379-86. 2012
    ..The aim of this study was to clarify the long-term clinical features of EMC treated at a single referral center using state-of-the-art techniques...
  40. doi Surgically resected solitary cavitary lung adenocarcinoma: association between clinical, pathologic, and radiologic findings and prognosis
    Yukio Watanabe
    Division of Pathology, National Cancer Center Hospital, Tokyo, Japan Division of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan Department of Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan
    Ann Thorac Surg 99:968-74. 2015
    ..The incidence of cavitary lung adenocarcinoma has recently increased; despite this, little is known about its clinical features and prognosis. We, therefore, evaluated the clinicopathologic features and prognosis of this malignancy...
  41. doi IDH1/2 mutation detection in gliomas
    Hideyuki Arita
    Department of Neurosurgery and Neuro Oncology, National Cancer Center Hospital, Tokyo, Japan
    Brain Tumor Pathol 32:79-89. 2015
    ..It is therefore important to acknowledge the advantages and disadvantages of each method. ..
  42. doi Cytokeratin 19 expression in primary thoracic tumors and lymph node metastases
    Kyohei Masai
    Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan Division of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan
    Lung Cancer 86:318-23. 2014
    ..To provide basic data for the development of this method for lung tumors, we conducted a large-scale investigation of cytokeratin (CK) 19 expression in thoracic tumors...
  43. doi Recycling and long-term storage of fluorescence in situ hybridization slides
    Susumu Wakai
    National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Am J Clin Pathol 141:374-80. 2014
    ..Although fluorescence in situ hybridization (FISH) technology is adequate, demand exists for additional recycling and long-term storage of FISH slides...
  44. doi Histological analysis suggests an invasion-independent metastatic mechanism in alveolar soft part sarcoma
    Nokitaka Setsu
    Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan
    Hum Pathol 45:137-42. 2014
    ..Because the latter mechanism is reportedly dependent on tumor angiogenesis and vascular remodeling, our data provide a morphological rationale for the use of anti-angiogenic therapy to treat ASPSs. ..
  45. doi Intratumoral distribution of EGFR-amplified and EGFR-mutated cells in pulmonary adenocarcinoma
    Shingo Soma
    Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan Division of General Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan
    Pathol Res Pract 210:155-60. 2014
    ..EGFR gene mutations preceded changes in oncogenic drive, more so than did EGFR gene number alterations during the developmental process of lung adenocarcinoma. ..
  46. doi Immunohistochemical actinin-4 expression in infiltrating gliomas: association with WHO grade and differentiation
    Shintaro Fukushima
    Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    Brain Tumor Pathol 31:11-6. 2014
    ..Although diagnostic utility of this marker awaits future exploration, actinin-4 may help distinguish between astrocytic and oligodendroglial lines of differentiation. ..
  47. doi Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours
    Akiko Matsubara
    Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan
    Histopathology 62:657-61. 2013
    ..To determine the prevalence of MED12 mutations in smooth muscle tumours of different organs...
  48. doi Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcoma
    Daisuke Kubota
    Division of Pharmacoproteomics, National Cancer Center Research Institute, Tokyo, Japan Department of Orthopedic Surgery, Juntendo University School of Medicine, Tokyo, Japan
    J Proteomics 91:393-404. 2013
    ..These findings indicated that PRDX2 would be a candidate biomarker of response to induction chemotherapy. Measurement of PRDX2 in open biopsy samples before treatment may contribute to risk stratification therapy for OS...
  49. doi Histological scoring for small lung adenocarcinomas 2 cm or less in diameter: a reliable prognostic indicator
    Akiko Miyagi Maeshima
    Clinical Laboratory Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuoku, 104 0045 Tokyo, Japan
    J Thorac Oncol 5:333-9. 2010
    ..Lung adenocarcinomas 2 cm or less in diameter were studied to develop histologic criteria predicting the outcome...
  50. doi Pfetin as a prognostic biomarker for gastrointestinal stromal tumor: validation study in multiple clinical facilities
    Daisuke Kubota
    Division of Pharmacoproteomics, National Cancer Center Research Institute, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Jpn J Clin Oncol 41:1194-202. 2011
    ..There is no biomarker predicting metastasis and/or recurrence of gastrointestinal stromal tumor though imatinib mesylate can improve recurrence-free survival...
  51. doi An analysis of factors related to the tail-like pattern of myxofibrosarcoma seen on MRI
    Kazutaka Kikuta
    Division of Orthopedic Surgery, National Cancer Center Hospital, 5 1 1, Chuo Ku, 104 0045, Tokyo, Japan
    Skeletal Radiol 44:55-62. 2015
    ..In this study, we performed a retrospective analysis to identify clinicopathological factors related to the tail-like pattern of the MRI findings in patients with MFS...
  52. pmc Prognostic significance of promyelocytic leukemia expression in gastrointestinal stromal tumor; integrated proteomic and transcriptomic analysis
    Hiroshi Ichikawa
    Division of Pharmacoproteomics, National Cancer Center Research Institute, Tokyo, Japan Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
    Cancer Sci 106:115-24. 2015
    ..Further validation studies of PML for clinical application, and investigation for the mechanistic significance of PML to clarify the molecular backgrounds of malignancy in GIST are warranted...
  53. doi Novel use for an EGFR mutation-specific antibody in discriminating lung adenocarcinoma from reactive pneumocyte hyperplasia
    Tomoyasu Mimori
    Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan Division of Endoscopy, Respiratory Endoscopy, National Cancer Research Institute, Tokyo, Japan
    Histopathology 66:816-23. 2015
    ..We hypothesized that these antibodies could be used to discriminate between ADCs and benign pneumocyte hyperplasias...
  54. doi Ciliated muconodular papillary tumors of the lung: a clinicopathologic analysis of 10 cases
    Tsugumasa Kamata
    Divisions of Pathology and Clinical Laboratories Thoracic Surgery Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine Department of Surgery, Division of General Thoracic Surgery, School of Medicine, Keio University, Tokyo, Japan
    Am J Surg Pathol 39:753-60. 2015
    ..CMPTs are rare, likely benign, underrecognized processes of the lung that should be distinguished from adenocarcinomas. ..
  55. doi Desmoplastic small round cell tumor with sphere-like clusters mimicking adenocarcinoma
    Yukinori Hattori
    Division of Pathology and Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan
    Diagn Cytopathol 43:214-7. 2015
    ..DSRCT should not be excluded from the differential diagnosis when sphere-like round cell clusters are observed in pleural or abdominal effusion, particularly in young male patients...
  56. doi Proteomics identified overexpression of SET oncogene product and possible therapeutic utility of protein phosphatase 2A in alveolar soft part sarcoma
    Daisuke Kubota
    Division of Pharmacoproteomics, National Cancer Center Research Institute, Tsukiji 5 1 1, Chuo Ku, Tokyo 104 0045, Japan
    J Proteome Res 13:2250-61. 2014
    ..We found that a PP2A activator, FTY720, decreased cell proliferation through apoptosis. Together, our findings may suggest the possible contribution of SET to the tumor progression and the utility of FTY720 for treatment of ASPS...
  57. doi Clinical relevance and therapeutic significance of microRNA-133a expression profiles and functions in malignant osteosarcoma-initiating cells
    Tomohiro Fujiwara
    Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan Department of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan
    Stem Cells 32:959-73. 2014
    ..Overall, silencing of miR-133a with concurrent chemotherapy would represent a novel strategy that targets multiple regulatory pathways associated with metastasis of the malignant cell population within osteosarcoma...
  58. doi Clinicopathologic analysis of spindle cell/sclerosing rhabdomyosarcoma
    Naoko Yasui
    Division of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan
    Pediatr Blood Cancer 62:1011-6. 2015
    ..Clinical characteristics and optimal treatment strategies for spindle cell/sclerosing rhabdomyosarcoma (ssRMS) have not been well established because of its rarity...
  59. doi Differential SALL4 immunoexpression in malignant rhabdoid tumours and epithelioid sarcomas
    Akihiko Yoshida
    Pathology and Clinical Laboratory, National Cancer Centre Hospital, Tokyo, Japan
    Histopathology 66:252-61. 2015
    ..Here, we evaluated the utility of SALL4 for differentiating MRTs from ESs, and compared its performance with that of CD34...
  60. doi Utility of PAX8 mouse monoclonal antibody in the diagnosis of thyroid, thymic, pleural and lung tumours: a comparison with polyclonal PAX8 antibody
    Akane Toriyama
    Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan Department of Pathology, Juntendo University Urayasu Hospital, Chiba, Japan
    Histopathology 65:465-72. 2014
    ..In addition, we analysed PAX8 mRNA expression by using in-situ hybridization...
  61. doi Soft-tissue hemangioblastoma of the retroperitoneum: a case study and review of the literature
    Akihiko Yoshida
    Clinical Laboratory Division, National Cancer Center Hospital, University of Tokyo, Tokyo, Japan
    Appl Immunohistochem Mol Morphol 18:479-82. 2010
    ..The patient is well 4 years after the surgery without any recurrence. A review of the literature revealed that soft-tissue hemangioblastoma is typically a solid tumor found in older females and often involves the retroperitoneum/pelvis...
  62. ncbi A case of endobronchial NUT midline carcinoma with intraluminal growth
    Sho Watanabe
    Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
    Anticancer Res 35:1607-12. 2015
    ..NUT midline carcinoma (NMC) is a rare, lethal form of differentiated squamous cell carcinoma characterized by chromosomal rearrangement of the NUT gene. Its highly aggressive nature commonly leads to unresectable and metastatic lesions...
  63. doi Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss
    Hideyuki Arita
    Department of Neurosurgery and Neuro Oncology, National Cancer Center, 5 1 1 Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    Acta Neuropathol 126:267-76. 2013
    ..Our results shed a new light on the role of telomerase activation in the development of adult gliomas...
  64. pmc Alveolar soft part sarcoma: a single-center 26-patient case series and review of the literature
    Koichi Ogura
    Division of Musculoskeletal Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Sarcoma 2012:907179. 2012
    ..Conclusions. ASPS is indolent but has a high propensity for metastasis. Early diagnosis and complete excision of the small primary tumor are essential in the treatment of ASPS...
  65. doi Secernin-1 as a novel prognostic biomarker candidate of synovial sarcoma revealed by proteomics
    Yoshiyuki Suehara
    Division of Pharmacoproteomics, National Cancer Center Research Institute, Japan
    J Proteomics 74:829-42. 2011
    ..These results indicate that secernin-1 may be used as a biomarker to predict the overall and metastasis-free survival in synovial sarcoma patients...